Home / コンテンツ / オンデマンド・ウェビナー / PBPK modeling approaches to assess risks associated with bioequivalence in drug development
PBPK modeling approaches to assess risks associated with bioequivalence in drug development
オンデマンド・ウェビナー

In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed:

  • Opportunities and challenges in conducting virtual bioequivalence
  • IVIVE-PBPK in biopharmaceutics
  • An quantitative risk assessment approach for virtual bioequivalence
  • Role of inter-occasion variability and pharmacokinetic properties in virtual bioequivalence
トップに戻る
Powered by Translations.com GlobalLink OneLink Software